ACR is now undervalued, IMO.
OBJ is valued at similar of ACR's. Mr Market always overacts bad news.
High volumes during last three days, suggest it may have a big movement ahead. ACR is still under ASX200, where instos can make money by shorting or going long.
Net cash around $34m ATM, my estimats. Also, the US$50m milstone payment is not entirely gone, likely just deferred one year as announced. give enterprise value around $80m, for a bio company that already has a product on sale.
Add to My Watchlist
What is My Watchlist?
